盐酸石蒜碱硫酯体内抗柯萨奇病毒A16的药效研究

doi:10.19803/j.1672-8629.20220625

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (1): 79-84.
DOI: 10.19803/j.1672-8629.20220625

盐酸石蒜碱硫酯体内抗柯萨奇病毒A16的药效研究

王辉强^1,2, 颜海燕^1,2, 李兴琼^1,2, 杨杰³, 李玉环^1,2,*

¹中国医学科学院北京协和医学院医药生物技术研究所, 中国医学科学院抗病毒药物研究重点实验室, 北京 100050;
²中国医学科学院北京协和医学院医药生物技术研究所, 抗感染药物研究北京市重点实验室, 北京 100050;
³山东达因海洋生物制药股份有限公司,山东荣成,264300

收稿日期:2022-10-24 发布日期:2023-01-19
通讯作者: ^*李玉环,女,博士,研究员,抗病毒药物药理学。E-mail: yuhuanlibj@126.com
作者简介:王辉强,男,博士,助理研究员,抗病毒药物药理学。
基金资助:
国家科技重大专项重大新药创制（2018ZX09721003-008-026）; 中国医学科学院医学与健康科技创新工程（2021-1-I2M-030）

Efficacy of lycorine thioester hydrochloride against coxsackievirus A16 in vivo

WANG Huiqiang^1,2, YAN Haiyan^1,2, LI Xingqiong^1,2, YANG Jie³, LI Yuhuan^1,2,*

¹Key Laboratory of Antiviral Drugs, Chinese Academy of Medical Sciences, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
²Beijing Key Laboratory of Anti-Infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
³Shandong DYNE Marine Biopharmaceutical Co., Ltd., Rongcheng Shandong 264300, China

Received:2022-10-24 Published:2023-01-19

摘要/Abstract

摘要： 目的研究盐酸石蒜碱硫酯在体内抗柯萨奇病毒A16（CVA16）的药效。方法通过腹腔注射病毒液方式感染10~11 d的ICR小鼠建立CVA16感染的小鼠模型。实验分为盐酸石蒜碱硫酯 1.0、0.5、0.25 mg·kg^-1组;50 mg·kg^-1 RBV对照组;病毒对照组;正常对照组。检测盐酸石蒜碱硫酯对病毒感染后小鼠发病情况、小鼠存活率和平均存活日;蛋白免疫印迹法（Western-blot）检测肌肉组织中病毒蛋白的表达水平;采用细胞病变效应法（CPE）测定肌肉组织中的病毒滴度;采用苏木素伊红（HE）染色检测肌肉组织的病理变化。结果与病毒对照组相比,盐酸石蒜碱硫酯 1.0 和0.5 mg·kg^-1剂量组能够显著降低小鼠肌肉组织的病毒滴度和病毒蛋白表达,降低CVA16感染造成的小鼠肌肉组织的炎症损伤,延缓小鼠的发病过程,显著延长小鼠的平均存活时间,增加小鼠的存活率,具有明确的保护作用。结论盐酸石蒜碱硫酯1.0 和0.5 mg·kg^-1剂量组对CVA16感染小鼠具有显著明确的保护作用,提示盐酸石蒜碱硫酯可能成为潜在的治疗手足口病的药物。

关键词: 盐酸石蒜碱硫酯, 柯萨奇病毒A16, 手足口病, 体内抗病毒药效, 小鼠

Abstract: Objective To investigate the efficacy of lycorine thioester hydrochloride against coxsackievirus A16 (CVA16) in vivo. Methods A mouse model of CVA16 infection was established via intraperitoneal injection of CVA16 in ICR mice aged 10 to 11 days. The experimental groups were divided into 1.0, 0.5 and 0.25 mg·kg^-1 lycorine thioester hydrochloride groups, 50 mg·kg^-1 RBV control group, virus control group, and the normal control group. The incidence of infections, survival rate and average survival of mice after virus infection were detected. The expression level of the viral protein in muscle tissue was detected by Western-blot assay. Cytopathic effect assay (CPE) was used to detect the viral titer in muscle tissue. Hematoxylin-eosin(HE) staining was used to detect the pathological changes of muscle tissue. Results Compared with the virus control group, administration of lycorine thioester hydrochloride 1.0 and 0.5 mg·kg^-1 could significantly reduce the viral titer and viral protein expression in muscle tissue, mitigate the inflammatory injury caused by CVA16 infection, delay the pathogenesis of mice, significantly prolong the average survival of mice, and increase the survival rate of mice. Conclusion Administration of lycorine thioester hydrochloride 1.0 and 0.5 mg·kg^-1 has a significant protective effect on CVA16-infected mice, suggesting that lycorine thioester hydrochloride may be a potential drug for the treatment of hand, foot, and mouth disease (HFMD).

Key words: lycorine thioester hydrochloride, coxsackievirus A16, hand, foot, and mouth disease, antiviral efficacy in vivo, mice

中图分类号:

R917
R978.7

王辉强, 颜海燕, 李兴琼, 杨杰, 李玉环. 盐酸石蒜碱硫酯体内抗柯萨奇病毒A16的药效研究[J]. 中国药物警戒, 2023, 20(1): 79-84.

WANG Huiqiang, YAN Haiyan, LI Xingqiong, YANG Jie, LI Yuhuan. Efficacy of lycorine thioester hydrochloride against coxsackievirus A16 in vivo[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 79-84.

参考文献

[1] ESPOSITO S, PRINCIPI N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention[J]. Eur J Clin Microbiol Infect Dis, 2018, 37(3): ???-???.
[2] CAI K, WANG Y, GUO Z, et al.Clinical characteristics and managements of severe hand, foot and mouth disease caused by enterovirus A71 and coxsackievirus A16 in Shanghai, China[J]. BMC Infect Dis, 2019, 19(1): 285.
[3] SOLOMON T, LEWTHWAITE P, PERERA D, et al.Virology, epidemiology, pathogenesis, and control of enterovirus 71[J]. Lancet Infect Dis, 2010, 10(11): 778-790.
[4] WU TN, TSAI SF, LI SF, et al.Sentinel surveillance for enterovirus 71, Taiwan, 1998[J]. Emerg Infect Dis, 1999, 5(?): 458-460.
[5] HE SJ, HAN JF, DING XX, et al.Characterization of enterovirus 71 and coxsackievirus A16 isolated in hand, foot, and mouth disease patients in Guangdong, 2010[J]. Int J Infect Dis, 2013, 17(11): e1025-e1030.
[6] XU W, LIU CF, YAN L, et al.Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications[J]. Virol J, 2012, 9: 8.
[7] HOOI YT, ONG KC, TAN SH, et al.Coxsackievirus A16 in a 1-Day-Old mouse model of central nervous system infection shows lower neurovirulence than enterovirus A71[J]. J Comp Pathol, 2020, 176: 19-32.
[8] LI ZQ, QIN ZQ, TAN HF, et al.Analysis of the coverage of inactivated enterovirus 71 (EV71) vaccine and adverse events following immunization with the EV71 vaccine among children from 2016 to 2019 in Guangzhou[J]. Expert Rev Vaccines, 2021, 20(7): 907-918.
[9] QING X, QING FC, WAN QY, et al.Interchangeability of two enterovirus 71 inactivated vaccines in Chinese children: a phase IV, open-label, and randomized controlled trial[J]. Vaccine, 2020, 38(12): 2671-2677.
[10] HU YF, JIA LP, YU FY, et al.Molecular epidemiology of coxsackievirus A16 circulating in children in Beijing, China from 2010 to 2019[J]. World J Pediatr, 2021,17(5): 508-516.
[11] YI L, ZENG H, ZHENG H, et al.Molecular surveillance of coxsackievirus A16 in southern China, 2008-2019[J]. Arch Virol, 2021, 166(6): 1653-1659.
[12] LIU J, YANG Y, XU Y, et al.Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication[J]. Virol J, 2011, 8: 483.
[13] LI SY, CHEN C, ZHANG HQ, et al.Identification of natural compounds with antiviral activities against SARS-associated coronavirus[J]. Antiviral Research, 2005, 67(1): 18-23.
[14] WANG P, LI LF, WANG QY, et al.Anti-dengue-virus activity and structure-activity relationship studies of lycorine derivatives[J]. Chem Med Chem, 2014, 9(7): 1522-1533.
[15] HE J, QI WB, WANG L, et al.Amaryllidaceae alkaloids inhibit nuclear-to-cytoplasmic export of ribonucleoprotein (RNP) complex of highly pathogenic avian influenza virus H5N1[J]. Influenza Other Respir Viruses, 2013, 7(6): 922-931.
[16] CHEN H, LAO Z, XU J, et al.Antiviral activity of lycorine against Zika virus in vivo and in vitro[J]. Virology, 2020, 546: 88-97.
[17] JIN YH, MIN JS, JEON S, et al.Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections[J]. Phytomedicine, 2021, 86:153440.
[18] WANG HQ, GUO TT, YANG YJ, et al.Lycorine derivative LY-55 inhibits CVA16 and CVA16 replication through downregulating autophagy[J]. Front Cell Infect Microbiol, 2019, 9: 277.
[19] REED LJ, MUENCH H.A simple method of estimating fifty percent endpoints[J]. Am J Epidemiol, 1938, 27: 493-497.
[20] XU L, SU WH, JIN J, et al.Identification of luteolin as enterovirus 71 and Coxsackievirus A16 inhibitors through reporter viruses and cell viability-based screening[J]. Viruse, 2014, 6(7): 2778-2795.
[21] WANG B, LI J, WANG Y, et al.Understanding the epidemiological characteristics of EV71 and CVA16 infection to aid the diagnosis and treatment of hand, foot, and mouth disease[J]. J Med Virol, 2019, 91(2): 201-207.
[22] WANG HQ, LIU SY, LI YH.Establishment of CVA16 animal models with 2-week-old ICR mice[J]. Chin Med Biotechnol(中国医药生物技术), 2018, 13(3): 268-271.

盐酸石蒜碱硫酯体内抗柯萨奇病毒A16的药效研究

Efficacy of lycorine thioester hydrochloride against coxsackievirus A16 in vivo

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孙绮悦, 赵荣华, 包蕾, 郭姗姗, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 基于多动物模型药效评价体系研究羚羊感冒口服液儿童用药剂量[J]. 中国药物警戒, 2024, 21(2): 121-126.
[2]	孙绮悦, 赵荣华, 郭姗姗, 包蕾, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 羚羊感冒口服液多重药理作用研究[J]. 中国药物警戒, 2024, 21(2): 127-131.
[3]	赵荣华, 孙静, 包蕾, 耿子涵, 陶夏莉, 张敬升, 庞博, 徐英莉, 曹姗, 李舒冉, 郭姗姗, 王道涵, 崔晓兰. 基于免疫调节探讨葛根汤颗粒治疗小鼠病毒性肺炎的作用机制[J]. 中国药物警戒, 2024, 21(2): 132-136.
[4]	曹姗, 庞博, 徐英莉, 张敬升, 陈梦苹, 张宇, 王雅欣, 包蕾, 耿子涵, 郭姗姗, 赵荣华, 崔晓兰. 疏风解毒胶囊预防给药对流感病毒感染小鼠模型TLR4介导肺组织炎性损伤的影响[J]. 中国药物警戒, 2024, 21(1): 45-50.
[5]	张敬升, 高双荣, 庞博, 刘莉娜, 徐英莉, 曹姗, 陈梦苹, 张宇, 赵荣华, 崔晓兰. 散寒化湿颗粒对人冠状病毒229E和OC43感染致小鼠肺炎的作用机制研究[J]. 中国药物警戒, 2024, 21(1): 51-54.
[6]	张亮亮, 胡昌坤, 吴泽坤, 周维, 廖泽彬, 高月. 富马酸二甲酯对肠道辐射损伤防护作用及机制研究[J]. 中国药物警戒, 2024, 21(1): 83-88.
[7]	殷玉玲, 胡楚涓, 张晓朦, 王雨, 张冰, 林志健. 菊苣提取物抗阿霉素心脏毒性作用挖掘及验证[J]. 中国药物警戒, 2023, 20(8): 858-865.
[8]	梅雨, 朱越, 张慧婷, 肖成荣, 高月, 马增春. 基于网络药理学和实验验证探讨中药复方CB001对低剂量辐射防护的作用机制[J]. 中国药物警戒, 2023, 20(8): 872-879.
[9]	杨明翰, 乔美玲, 骆骄阳, 杨美华, 盛萍. 多伞阿魏抗胃癌活性部位的急性毒性试验研究[J]. 中国药物警戒, 2023, 20(8): 880-884.
[10]	沈宁宁, 刘昱甫, 茹毅, 师卓, 杨春启, 倪喆鑫, 肖成荣, 马增春, 王宇光, 高月. 麦冬皂苷D对小鼠力竭游泳抗疲劳作用的研究[J]. 中国药物警戒, 2023, 20(7): 749-753.
[11]	王荣, 刘自群, 王娜娜, 谭雄, 张怡心, 杨宽, 秦蓓. 脯氨酸丹参素冰片酯对小鼠急性毒性研究[J]. 中国药物警戒, 2023, 20(7): 754-757.
[12]	左泽平, 田颖颖, 徐意, 姜克武, 杨硕, 杨海润, 张志聪, 曹欣垚, 吴笑如, 王志斌. 金匮肾气丸临床前安全性评价研究[J]. 中国药物警戒, 2023, 20(7): 775-782.
[13]	辛雨濛, 卢天公, 孙震晓. 甘草干姜汤对顺铂所致巨噬细胞毒性的保护作用[J]. 中国药物警戒, 2023, 20(6): 661-670.
[14]	赵荣华, 孙静, 包蕾, 耿子涵, 李贵平, 王道涵, 李舒冉, 张敬升, 庞博, 徐英莉, 周利润, 鲍岩岩, 陈梦苹, 郭姗姗, 崔晓兰. 金振口服液对人冠状病毒肺炎热毒疫幼龄小鼠模型的干预机制[J]. 中国药物警戒, 2023, 20(3): 248-252.
[15]	何慧, 柴媛媛, 徐云霞, 俞沁玮, 黄鑫, 张陆勇, 江振洲. 基于LC-MS/MS同时测定小鼠血浆中对乙酰氨基酚及其毒性代谢产物对乙酰氨基酚半胱氨酸的浓度[J]. 中国药物警戒, 2023, 20(3): 266-272.